Adverum Biotechnologies
Biotechnology, 800 Saginaw Dr, Redwood City, California, 94063, United States, 51-200 Employees
Phone Number: 65********
Who is ADVERUM BIOTECHNOLOGIES
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration o...
Read More
-
Headquarters: 800 Saginaw Dr, Redwood City, California, 94063, United States
-
Date Founded: 2012
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from ADVERUM BIOTECHNOLOGIES
Adverum Biotechnologies Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Adverum Biotechnologies
Answer: Adverum Biotechnologies's headquarters are located at 800 Saginaw Dr, Redwood City, California, 94063, United States
Answer: Adverum Biotechnologies's phone number is 65********
Answer: Adverum Biotechnologies's official website is https://adverum.com
Answer: Adverum Biotechnologies's revenue is $1 Million to $5 Million
Answer: Adverum Biotechnologies's SIC: 2836
Answer: Adverum Biotechnologies's NAICS: 621111
Answer: Adverum Biotechnologies has 51-200 employees
Answer: Adverum Biotechnologies is in Biotechnology
Answer: Adverum Biotechnologies contact info: Phone number: 65******** Website: https://adverum.com
Answer: Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month